

*This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.*

# Bibliography

SCHIZOPHRENIA

Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. Functional coprimary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. *Am J Psychiatry* 2008; 165:221–228

**Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. *Schizophr Bull* 2007; 33:21–32** Available online at <http://schizophreniabulletin.oxfordjournals.org/cgi/content/full/33/1/21>

Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. *Schizophr Bull* 2007; 33:1120–1130

Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. *J Clin Psychiatry* 2007; 68:815–825

Craddock N, O'Donovan MC, Owen MJ. Phenotypic and genetic complexity of psychosis. Invited commentary on . . . Schizophrenia: a common disease caused by multiple rare alleles. *Br J Psychiatry* 2007; 190:200–203

Elkis H. Treatment-resistant schizophrenia. *Psychiatr Clin North Am* 2007; 30:511–33

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (CATIE Investigators; Neurocognitive Working Group). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. *Arch Gen Psychiatry* 2007; 64:633–647

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry* 2007; 164:1061–1071

**Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment refractory schizophrenia. *Psychiatr Serv* 2007; 58:983–990**

**Malik P. Sexual dysfunction in schizophrenia. *Curr Opin Psychiatry* 2007; 20:138–142**

McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry* 2007; 164:1050–1060

McGurk SR, Twamley EW, Sitzler DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry* 2007; 164:1791–1802

**Stover EL, Brady L, Marder SR. New paradigms for treatment development. *Schizophr Bull* 2007; 33:1093–1099** Available online at <http://schizophreniabulletin.oxfordjournals.org/cgi/content/abstract/33/5/1093>

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK (CATIE Investigators). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. *Am J Psychiatry* 2007; 164:415–427

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA (CATIE Investigators). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. *Am J Psychiatry* 2007; 164:428–436

Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. *Schizophr Bull* 2007; 33:69–94

Weiden PJ, Buckley PF, Grody M. Understanding and treating “first-episode” schizophrenia. *Psychiatr Clin North Am* 2007; 30:481–510

**Brown AS: Prenatal infection as a risk factor for schizophrenia. *Schizophr Bull* 2006; 32:200–202**

Available online at  
<http://schizophreniabulletin.oxfordjournals.org/cgi/content/full/32/2/200>

**Fenton WS, Chavez MR. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. *Am J Psychiatry* 2006; 163:1697–1704**

Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB (HGDH Study Group). Olanzapine and haloperidol in first episode psychosis: two-year data. *Schizophr Res* 2006; 86:234–243

Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R (Clozapine and Risperidone Enhancement (CARE) Study Group). Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med* 2006; 354:472–482

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry* 2006; 63:1079–1087

Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICES consensus statement on negative symptoms. *Schizophr Bull* 2006; 32:214–219

Marder SR. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. *J Clin Psychiatry* 2006; 67:e03

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (CATIE Investigators). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006; 163:600–610

**Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. *Psychiatr Serv* 2006; 57:1482–1487**

Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. *Schizophr Res* 2006; 88:5–25

Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. *Can J Psychiatry* 2006; 51: 480–491

Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. *Curr Opin Psychiatr*. 2006; 19:158–164

Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. *Arch Gen Psychiatry* 2006; 63:679–685

Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. *Am J Psychiatry* 2006; 163:2096–2102

Shad MU, Tamminga CA, Cullum M, Haas GL, Keshavan MS. Insight and frontal cortical function in schizophrenia: a review. *Schizophr Res* 2006; 86:54–70

Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. *Br J Psychiatry* 2006; 188: 510–518

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (CATIE Investigators). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006; 163:611–622

Tamminga CA. The neurobiology of cognition in schizophrenia. *J Clin Psychiatry* 2006; 67:e11

**Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. *Am J Psychiatry* 2006; 163:365–373**

Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus. *Am J Psychiatry* 2005; 162:441–449

Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR. A summary of the FDA-NIMH-MATRICES workshop on clinical trial design for neurocognitive drugs for schizophrenia. *Schizophr Bull* 2005; 31:5–19

Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. *J Med Genet* 2005; 42:193–204

Elbogen EB, Swanson JW, Swartz MS, Van Dorn R. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. *J Nerv Ment Dis* 2005; 193:673–679

Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich L-A. Pregnancy, delivery and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. *Am J Psychiatry* 2005; 162:79–91

- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353:1209–1223
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res* 2005; 80:19–32
- Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs* 2005; 19(suppl 1):1–93
- Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. *Am J Psychiatry* 2005; 162:2220–2232
- Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. *Am J Psychiatry* 2005; 162: 1785–1804
- Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (Early Psychosis Global Working Group). Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. *Am J Psychiatry* 2005; 162:947–953
- Asarnow JR, Tompson MC, McGrath EP. Annotation: childhood onset schizophrenia: clinical and treatment issues. *J Child Psychol Psychiatry* 2004; 45:180–194
- Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. *Am J Psychiatry* 2004; 161:414–425
- Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004; 161:1334–1349
- Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. *J Clin Psychopharmacol* 2004; 23(5 suppl 1):S1–S6
- Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. *Science* 2004; 306:443–447
- Ridderinkhof KR, van den Wildenberg WP, Segalowitz SJ, Carter CS. Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. *Brain Cogn* 2004; 56:129–140
- Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2004; 161: 473–479
- Vauth R, Loschmann C, Rusch N, Corrigan PW. Understanding adherence to neuroleptic treatment in schizophrenia. *Psychiatry Res* 2004; 126:43–49
- Hyman SE, Fenton WS. Medicine: what are the right targets for psychopharmacology? *Science* 2003; 299: 350–351
- Palmer BW, McClure FS, Jeste DV. Schizophrenia in late life: findings challenge traditional concepts. *Harv Rev Psychiatry* 2001; 9:51–58
- Howard P, Rabins PV, Seeman MV, Jeste DP (International Late-Onset Schizophrenia Group). Late-onset schizophrenia and very late-onset schizophrenia-like psychosis: an international consensus. *Am J Psychiatry* 2000; 157:172–178
- Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. *Neuropsychopharmacology* 1999; 20:106–118
- Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry* 1996; 153:321–330
- Liddle PF. The symptoms of chronic schizophrenia: A re-examination of the positive and negative dichotomy. *Br J Psychiatry* 1987; 151:145–151

## NOTES